U.S. Preclinical CRO Market Analysis Report 2024-2030: Bioanalysis & DMPK Studies, Toxicology Testing - Life Science Firms Shift Focus To Core Competencies To Boost Efficiency And Innovation

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By Model Type, By Technology, By End-use, By State, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
The U.S. preclinical CRO market size is anticipated to reach USD 5.9 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030

Factors such as the increasing expenditure on R&D activities and the focus of pharmaceutical companies on cost reduction are driving the market growth.

There has been a significant increase in the R&D budget for early-stage and late-stage drug development processes, which is expected to contribute to market growth. The rising biopharmaceutical failure rates and the costs they entail have also driven the biopharmaceutical & life sciences companies to focus more on the early stage of the drug discovery and development process. This is likely to propel the growth of the market for preclinical CRO.
The increasing cases of Alzheimer's disease globally, demand for cutting-edge gene therapies, incidence of neurodegenerative diseases, and high prevalence of genetic disorders are some of the factors promoting the growth of advanced therapies. A substantial number of major & small biotechnology companies are driving innovation in this field in terms of technology & manufacturing capabilities, thereby offering commercial opportunities for market expansion.
Furthermore, the recent approval of new products has accelerated R&D activities. For instance, in December 2023, the FDA approved two groundbreaking treatments-Casgevy and Lyfgenia. These treatments mark a significant milestone as the first cell-based gene therapies suggested for the treatment of sickle cell disease in patients aged 12 and older.
U.S. Preclinical CRO Market Report Highlights

• Discovery research dominated the service segment with 29.6% share in 2023, owing to the rising trend of outsourcing research in the biotechnology and pharmaceutical companies to accelerate drug discovery and reduce cost.
• The bioanalysis and DMPK studies segment is expected to witness the fastest CAGR over the forecast period, owing to widescale applications of CROs in bioanalysis studies.
• Increasing demand for personalized medicine and advanced therapeutics, life science companies focusing on their core competencies, and the increasing trend of outsourcing are expected to drive the market growth over the forecast period.
• In August 2022, WuXi STA announced its new 190-acre pharmaceutical manufacturing campus in the U.S. This site would be its second facility, offering expanded capacity and flexibility to meet customers' needs in the U.S. and across the globe.

Companies Featured

• Laboratory Corporation of America
• Lonza
• WuXi AppTec, Inc.
• Eurofins Scientific SE
• Intertek Group plc
• Medpace Holdings, Inc.
• Charles River Laboratories International, Inc.
• SGA SA
• Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
• ICON plc
• CROWN bioscience

Key Attributes:

Report Attribute	Details
No. of Pages	80
Forecast Period	2023 - 2030
Estimated Market Value (USD) in 2023	$3.6 Billion
Forecasted Market Value (USD) by 2030	$5.9 Billion
Compound Annual Growth Rate	7.1%
Regions Covered	United States

Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Services outlook
2.2.2. Model Type outlook
2.2.3. Technology outlook
2.2.4. End-use outlook
2.2.5. States outlook
2.3. Competitive Insights
Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising outsourcing trend
3.2.1.2. Increasing focus of life science companies on their core competencies
3.2.1.3. Increasing demand of personalized medicine and advanced therapeutics
3.2.1.4. Increasing pharmaceutical R&D investments
3.2.2. Market restraint analysis
3.2.2.1. Monitoring issues and lack of standardization
3.2.2.2. Managing relationships
3.3. U.S. Preclinical CRO Market Analysis Tools
3.3.1. Industry analysis - Porter's
3.3.2. PESTEL analysis
Chapter 4. U.S. Preclinical CRO Market: Services Estimates & Trend Analysis
4.1. Services Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Preclinical CRO Market by Services Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Bioanalysis and DMPK studies
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. In vitro ADME
4.4.1.3. In-vivo PK
4.4.2. Toxicology testing
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. GLP
4.4.2.3. Non-GLP
4.4.3. Compound management
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.2. Process R&D
4.4.3.3. Custom synthesis
4.4.4. Chemistry
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4.2. Medicinal chemistry
4.4.4.3. Computation chemistry
4.4.5. Safety pharmacology
4.4.6. Discovery research
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6.2. Target identification & screening
4.4.6.3. Target validation & functional informatics
4.4.6.4. Lead identification & candidate optimization
4.4.6.5. Preclinical development
4.4.6.6. Other associated workflow
Chapter 5. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis
5.1. Model Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Preclinical CRO Market by Model Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Small animal models
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Mice
5.4.1.3. Rats
5.4.1.4. Rabbits
5.4.2. Large animal models
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Pig
5.4.2.3. Others
5.4.3. Organoid models
5.4.4. Cell culture models
5.4.5. Others
Chapter 6. U.S. Preclinical CRO Market: Technology Estimates & Trend Analysis
6.1. Technology Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Preclinical CRO Market by Technology Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. In vivo studies
6.4.2. In vitro studies
6.4.3. Ex vivo studies
6.4.4. Imaging technologies
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4.2. Ultrasound imaging
6.4.4.3. MRI imaging
6.4.4.4. CT imaging
6.4.4.5. Radionuclide imaging
6.4.4.6. Other imaging technologies
Chapter 7. U.S. Preclinical CRO Market: End-use Estimates & Trend Analysis
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. U.S. Preclinical CRO Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Biopharmaceutical companies
7.4.2. Research and academic institutes
7.4.3. Medical device companies
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Company overview
8.4.2. Financial performance
8.4.3. Product benchmarking
8.4.4. Strategic initiatives

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• U.S. Preclinical CRO Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN04102024004107003653ID1108746296